Biotech
Tune Therapeutics
Tune Therapeutics raises $175M Series B at $900M valuation
Durham, NCFebruary 12, 20251 min read
Total Raised
$175M
Valuation
$900M
Latest Round
Series B
Employees
100+
Tune Therapeutics: Series B Funding Round
Tune Therapeutics has successfully raised $175M in Series B funding, reaching a valuation of $900M.
Company Overview
Epigenetic gene regulation therapies
Funding Details
The Series B round was led by Hevolution, with participation from NEA, Regeneron Ventures.
Company Information
- Headquarters: Durham, NC
- Founded: 2021
- Employees: 100+
- Category: Biotech
Investment
Tune Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Hevolution: Verified investor in Series B
- NEA: Verified investor in Series B
- Regeneron Ventures: Verified investor in Series B
Company Info
Headquarters
Durham, NC
Founded
2021
Team Size
100+
Last Round
$175M(Feb 2025)
Investors (3)
H
HevolutionLeadLead Investor
Verified investor in Series B
N
NEAInvestor
Verified investor in Series B
R
Regeneron VenturesInvestor
Verified investor in Series B
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free